Insmed (INSM) Stock Price, News & Analysis

Company Overview

Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for patients with serious and rare diseases. The company’s research and development activities center on pulmonary and inflammatory conditions, with an emphasis on diseases that have limited treatment options.

Insmed’s principal commercial product is ARIKAYCE liposomal, an inhaled formulation of amikacin used with a combination antibacterial regimen to treat refractory Mycobacterium avium complex lung disease in certain adult patients. The product is marketed in the United States and has also received regulatory authorization in other major markets, including Europe and Japan.

The company is also advancing a pipeline of investigational therapies, including brensocatib, an oral anti-inflammatory treatment being developed for bronchiectasis, and treprostinil palmitil inhalation powder, an inhaled therapy being studied for pulmonary arterial hypertension and other pulmonary conditions. Insmed is headquartered in Bridgewater, New Jersey, and is led by President and Chief Executive Officer Will Lewis.

Key Stats

• Today's Range: $108.48 to $116.19
• 50-Day Range: $98.45 to $134.75
• 52-Week Range: $90.39 to $212.75
• Volume: 2.65 million shs
• Average Volume: 2.06 million shs
• Market Capitalization: $23.71 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $200.57
• Consensus Rating: Buy

Insmed Stock Analysis - MarketRank™

Insmed scored higher than 69% of companies evaluated by MarketBeat, and ranked 202nd out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Insmed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 22 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Insmed has a consensus price target of $200.57, representing about 84.7% upside from its current price of $108.59.

Amount of Analyst Coverage

Insmed has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Insmed are expected to grow in the coming year, from ($1.84) to $0.96 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Insmed is -26.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Insmed is -26.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Insmed has a P/B Ratio of 31.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.05% of the float of Insmed has been sold short.

Short Interest Ratio / Days to Cover

Insmed has a short interest ratio ("days to cover") of 5.27.

Change versus previous month

Short interest in Insmed has recently decreased by 5.58%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Insmed does not currently pay a dividend.

Dividend Growth

Insmed does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.59

News Sentiment

Insmed has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Insmed this week, compared to 9 articles on an average week.

Search Interest

26 people have searched for INSM on MarketBeat in the last 30 days. This is an increase of 4% compared to the previous 30 days.

MarketBeat Follows

Only 6 people have added Insmed to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Insmed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $36,320,872.00 in company stock.

Percentage Held by Insiders

2.10% of the stock of Insmed is held by insiders.

Percentage Held by Institutions

Insmed has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/02/2026
• Next Earnings (Estimated): 10/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:INSM
• CIK: 1104506
• Web: www.insmed.com
• Phone: 908-977-9900
• Fax: 732-438-0381
• Employees: 1,664
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Insmed: $200.57
• High Price Target: $263.00
• Low Price Target: $167.00
• Potential Upside/Downside: +84.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 25 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.28 billion
• Net Margins: -76.94%
• Pretax Margin: -76.40%
• Return on Equity: -123.94%
• Return on Assets: -44.30%

Debt

• Debt-to-Equity Ratio: 0.74
• Current Ratio: 3.72
• Quick Ratio: 3.40

Sales & Book Value

• Annual Sales: $606.42 million
• Price / Sales: 39.10
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.46 per share
• Price / Book: 31.38

Miscellaneous

• Outstanding Shares: 218,380,000
• Free Float: 213,796,000
• Market Cap: $23.71 billion
• Optionable: Optionable
• Beta: 0.83